QuantumSi Inc
$ 0.91
-3.07%
23 Feb - close price
- Market Cap 196,505,000 USD
- Current Price $ 0.91
- High / Low $ 0.95 / 0.90
- Stock P/E N/A
- Book Value 1.09
- EPS -0.67
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.52 %
- 52 Week High 3.10
- 52 Week Low 0.89
About
Quantum-Si incorporated operates the first next-generation protein sequencing platform for the healthcare industries.
Analyst Target Price
$2.68
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-05 | 2025-05-07 | 2025-02-26 | 2024-11-12 | 2024-08-07 | 2024-05-09 | 2024-02-29 | 2023-11-09 | 2023-08-07 | 2023-05-11 | 2023-03-06 |
| Reported EPS | -0.17 | -0.16 | -0.1088 | -0.1636 | -0.1778 | -0.16 | -0.14 | -0.16 | -0.17 | -0.18 | -0.17 | -0.24 |
| Estimated EPS | -0.13 | -0.14 | -0.14 | -0.19 | -0.19 | -0.19 | -0.2 | -0.18 | -0.19 | -0.2 | -0.19 | -0.2 |
| Surprise | -0.04 | -0.02 | 0.0312 | 0.0264 | 0.0122 | 0.03 | 0.06 | 0.02 | 0.02 | 0.02 | 0.02 | -0.04 |
| Surprise Percentage | -30.7692% | -14.2857% | 22.2857% | 13.8947% | 6.4211% | 15.7895% | 30% | 11.1111% | 10.5263% | 10% | 10.5263% | -20% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QSI
2026-02-08 07:27:41
Quantum-Si Incorporated has announced the release of two new manuscripts highlighting the utility of its single-molecule protein sequencing technology. One paper, published in the Journal of Analytical Chemistry, demonstrates the technology's effectiveness in identifying clinically relevant hemoglobin variants. The company believes this advancement positions its protein sequencing technology as a valuable tool for clinical proteomics and hemoglobinopathy research.
2026-01-09 12:58:25
Quantum-Si (NASDAQ:QSI) experienced a 14% share price climb in the past week, adding US$32 million to its market capitalization. However, long-term investors from five years ago are still down by 88%. Despite strong revenue growth of 77% per year over the last five years, the stock has underperformed, leading to questions about its long-term recovery potential.
2025-12-23 14:09:13
Jeffrey Alan Hawkins, President and CEO of Quantum-Si Inc (NASDAQ:QSI), sold 23,707 shares for a total of $30,250 on December 22, 2025. This sale was a mandatory sell-to-cover provision for tax purposes related to restricted stock units. Quantum-Si recently reported a larger-than-expected Q3 2025 loss and is progressing with its Proteus protein analysis platform, with H.C. Wainwright reiterating a "Buy" rating.
2025-12-23 14:08:40
Jeffrey Alan Hawkins, President and CEO of Quantum-Si Inc. (NASDAQ:QSI), sold 23,707 shares of Class A Common Stock for approximately $30,250 on December 22, 2025. This sale was a mandatory "sell-to-cover" provision for tax withholding related to restricted stock units. The company recently reported a larger-than-expected Q3 2025 loss and revenue shortfall but is progressing with its Proteus protein analysis platform.
2025-12-23 10:09:53
Quantum-Si Incorporated (Nasdaq: QSI) has launched its Version 3 Library Preparation Kit and a new suite of data analysis tool enhancements, significantly improving protein analysis. The new kit requires 100-fold less protein input and enables detection of proteins with as little as 1-2 ng, greatly benefiting scarce biologic sample processing. These advancements allow for better detection of low abundance biomarkers and expand amino acid coverage to 15, with a goal of all 20 by 2026.
2025-12-23 01:08:39
John S. Vieceli, Chief Product Officer of Quantum-Si Inc (NASDAQ:QSI), sold 21,927 shares for approximately $27,978 on December 22, 2025, to cover tax obligations related to restricted stock units. Despite this, he still directly owns 800,973 shares. While the company holds more cash than debt, it is quickly burning through cash and is not profitable yet, though it is considered slightly undervalued by InvestingPro analysis.
